Before Invest
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON

JNJ
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 28, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance Sheet
Period
Annual Quarterly
Order
Unlock 14 years
Format
% Change
Rows
USD ($)
$ in Millions 		Dec 28, 2025Dec 29, 2024Dec 31, 2023Jan 1, 2023Jan 2, 2022Jan 3, 2021Dec 29, 2019Dec 30, 2018Dec 31, 2017Jan 1, 2017Jan 3, 2016Dec 28, 2014Dec 29, 2013Dec 30, 2012Jan 1, 2012Jan 2, 2011Jan 3, 2010
Current assets:
                 
Cash and cash equivalents
$ 19,709
$ 24,105
$ 21,859
Marketable securities
393
417
1,068
Accounts receivable trade, less allowances $183 (2024, $167)
17,178
14,842
14,873
Inventories
14,191
12,444
11,181
Deferred taxes on income (Note 8)
-
-
-
Prepaid expenses and other receivables
4,153
4,085
4,514
Total current assets of discontinued operations
-
-
0
Assets held for sale (Note 18)
-
-
-
Total current assets
55,624
55,893
53,495
Property, plant and equipment, net
23,169
20,518
19,898
Intangible assets, net
50,403
37,618
34,175
Goodwill
48,772
44,200
36,558
Deferred taxes on income
6,874
10,461
9,279
Other assets
14,368
11,414
14,153
Noncurrent assets of discontinued operations
-
-
0
Total assets
199,210
180,104
167,558
Liabilities and Shareholders’ Equity
                 
Current liabilities
                 
Loans and notes payable
8,495
5,983
3,451
Accounts payable
11,991
10,311
9,632
Accrued liabilities
8,594
8,549
10,212
Accrued rebates, returns and promotions
19,124
17,580
16,001
Accrued compensation and employee related obligations
4,534
4,126
3,993
Accrued taxes on income
1,388
3,772
2,993
Current liabilities of discontinued operations
-
-
0
Total current liabilities
54,126
50,321
46,282
Long-term debt
39,438
30,651
25,881
Deferred taxes on income
6,791
2,448
3,193
Employee related obligations
6,957
7,255
7,149
Long-term taxes payable
486
390
2,881
Other liabilities
9,868
17,549
13,398
Noncurrent liabilities of discontinued operations
-
-
0
Total liabilities
117,666
108,614
98,784
Shareholders’ equity
                 
Preferred stock — without par value (authorized and unissued 2,000,000 shares)
0
0
0
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)
3,120
3,120
3,120
Accumulated other comprehensive income (loss)
(14,930)
(11,741)
(12,527)
Retained earnings and Additional-paid-in-capital
168,978
155,791
153,843
Stockholders' Equity before Treasury Stock
-
-
-
Less: common stock held in treasury, at cost (Note 12) (711,904,000 shares and 712,921,000 shares)
75,624
75,680
75,662
Total shareholders’ equity
81,544
71,490
68,774
Total liabilities and shareholders’ equity
$ 199,210
$ 180,104
$ 167,558
Preferred stock, shares authorized (in shares)
-
-
-
Common Stock, Par or Stated Value Per Share
-
-
-
Common Stock, Shares Authorized
-
-
-
Common Stock, Shares, Issued
-
-
-